Literature DB >> 2576040

The disposition of the enantiomers of warfarin following chronic administration to rats: relationship to anticoagulant response.

S K Pratt1, M J Winn, B K Park.   

Abstract

A model of chronic anticoagulation has been used to investigate the whole liver and subcellular disposition of the individual enantiomers of warfarin in the Wistar rat in relation to anticoagulant response. Consistent pharmacodynamic responses were achieved by dosing daily with R-warfarin (0.4, or 0.8 mg kg-1 day-1 i.p.) or S-warfarin (0.1 mg kg-1 day-1 i.p.). After the administration of increasing doses of R-warfarin, prothrombin times were dose-dependent (16.3 +/- 0.5 s, 0.1 mg kg-1 day-1; 21.6 +/- 1.7 s, 0.4 mg kg-1 day-1; 55.1 +/- 9.0 s, 0.8 mg kg-1 day-1; results all measured 24 h after the final dose). Increasing doses of R-warfarin also produced increases in plasma, whole liver, and cytosolic concentrations of warfarin. However, there were no significant differences between the microsomal concentrations of R-warfarin in the three groups. The dose of S-warfarin required to produce a consistent and significant increase in the prothrombin time was four-fold lower than the dose of R-warfarin required to cause a similar effect. Plasma concentrations of S-warfarin were not significantly different from those seen after 0.4 mg kg-1 day-1 R-warfarin. Whole liver and cytosolic concentrations of the S-enantiomer were lower than those observed after a dose of 0.4 mg kg-1 day-1 R-warfarin. However, consistent with microsomal concentrations following increasing doses of R-warfarin, there was no significant difference between microsomal concentrations of R(+)- and S(-)-warfarin.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2576040     DOI: 10.1111/j.2042-7158.1989.tb06357.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  1 in total

1.  Dose-dependent pharmacokinetics of warfarin in healthy volunteers.

Authors:  S Y King; M A Joslin; K Raudibaugh; H J Pieniaszek; I H Benedek
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.